Core Insights - Guardian Pharmacy Services (GRDN) reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.24 per share, and a significant improvement from a loss of $2 per share a year ago [1] - The company achieved revenues of $377.43 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.63% and showing growth from $314.39 million in the same quarter last year [3] - Guardian Pharmacy's stock has increased by approximately 42.2% since the beginning of the year, outperforming the S&P 500's gain of 14.4% [4] Earnings Performance - The earnings surprise for the recent quarter was +4.17%, following a previous surprise of +4.55% when earnings were $0.23 per share against an expectation of $0.22 [2] - Over the last four quarters, Guardian Pharmacy has exceeded consensus EPS estimates three times [2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.25, with expected revenues of $372.06 million, and for the current fiscal year, the estimate is $0.95 on $1.4 billion in revenues [8] - The estimate revisions trend for Guardian Pharmacy was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [7] Industry Context - Guardian Pharmacy operates within the Zacks Medical - Drugs industry, which is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The performance of Guardian Pharmacy's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [6][9]
Guardian Pharmacy Services (GRDN) Q3 Earnings and Revenues Surpass Estimates